Skip to main content

Security report for biogen.uy

Biogen · Healthcare · Uruguay

Low risk. 2 critical or high findings in Email security and SSL/TLS.

Security score

82/100

Risk levelLow

0–100, higher is better. How it is calculated

Biogen Uruguay is a regional website for Biogen, a global leader in biotechnology founded in 1978. The company specializes in innovative therapies for complex neurological and rare diseases, including multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. The website targets a general audience including healthcare professionals and patients in Uruguay, providing information about the company's mission, therapeutic areas, and corporate responsibility. The business model is focused on pharmaceutical innovation and patient care, supported by a strong global presence and regional localization. Technically, the website is built on Adobe Experience Manager CMS, leveraging modern JavaScript libraries such as jQuery and Adobe Helix RUM for performance monitoring. It uses Cookiebot for GDPR-compliant cookie consent management and integrates Google Analytics and Google Tag Manager for analytics and marketing. The site is hosted on AWS infrastructure, inferred from load balancer cookies. The site demonstrates good mobile optimization and SEO practices, though accessibility features are basic. From a security perspective, the site enforces HTTPS and uses HttpOnly cookies to protect session data. However, no explicit security headers were detected in the HTML content, and there is no visible security policy or incident response contact information. The cookie consent mechanism is robust and GDPR compliant. No vulnerabilities or exposed sensitive data were found. The WHOIS data is consistent with the business claims, showing a legitimate and established domain. Overall, the website presents a professional and trustworthy digital presence for Biogen in Uruguay, with strong privacy compliance and good technical implementation. Recommendations include enhancing security headers, publishing a security policy, and adding vulnerability disclosure information to further improve security posture and trust.

Scanned

NIS2 and GDPR posture

GDPR outside view
83/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching biogen.uy

This scan found 16 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
77
Security headers
95
Email security
60
DNS health
75
Network security
100
GDPR outside view
83
Average
82

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Biogen holds a strong market position as a global biotechnology leader with a focus on neurological and rare diseases. The company leverages innovation and scientific research to develop transformative therapies. The website reflects a business model centered on pharmaceutical R&D and patient-centric care. The presence of multiple regional domains indicates a broad international footprint. The company targets healthcare professionals, patients, and stakeholders interested in biotech innovation. The site’s content and navigation support brand consistency and engagement. Partnerships and regional localization enhance market penetration. The absence of direct contact emails or phone numbers on the homepage suggests controlled communication channels, likely via contact forms or regional offices.

Security posture

The website demonstrates a mature security posture with mandatory HTTPS and secure cookie attributes. The use of Cookiebot ensures compliance with privacy regulations and user consent management. However, the lack of visible security headers such as Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options represents an area for improvement. No incident response or security contact information is published, which could hinder timely vulnerability reporting. No security.txt or vulnerability disclosure policy is present. Overall, the site is secure but could benefit from enhanced security best practices and transparency to strengthen trust and incident readiness.

Recommendations

  1. Implement and configure security headers including Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options to mitigate common web attacks.
  2. Publish a clear security policy and provide dedicated incident response contact channels (e.g., security@biogen.uy) to facilitate vulnerability reporting.
  3. Add a vulnerability disclosure or security.txt file to encourage responsible security research and improve transparency.
  4. Enhance accessibility features to improve compliance with WCAG standards and broaden user inclusivity.
  5. Regularly audit third-party scripts and libraries to ensure no vulnerable components are used and maintain up-to-date dependencies.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Biogen
Description
Biogen es una empresa líder en biotecnología a nivel global, pionera en la ciencia y que impulsa innovaciones para enfermedades complejas y devastadoras. Biogen avanza continuamente en el desarrollo de posibles terapias en neurología, neuropsiquiatría, inmunología especializada y enfermedades raras, manteniendo enfoque en su propósito de servir a la humanidad a través de la ciencia, promoviendo así un mundo más saludable, sostenible y equitativo.
Key services
medicamentos para esclerosis múltiple, tratamientos para atrofia muscular espinal, terapias para enfermedad de Alzheimer, innovación en neurología, neuropsiquiatría, inmunología y enfermedades raras
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.6.4, Adobe Helix RUM, Cookiebot, Google Tag Manager, Google Analytics
Frameworks
Adobe Experience Manager (AEM)
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • HttpOnly cookies
  • Cookie consent mechanism

Analytics and tracking

Services
Google Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cookiebot
Marketing tools
Cookiebot
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is professionally designed and well-structured
  2. Comprehensive cookie consent and privacy policies in Spanish
  3. No direct company emails or phone numbers found on homepage; contact form available
  4. Strong presence of social media links to official Biogen accounts
  5. Use of modern web technologies and Adobe Experience Manager CMS
  6. Good GDPR compliance with cookie consent and privacy notices
  7. No visible security headers detected in HTML content
  8. No vulnerability disclosure or security.txt found
  9. No signs of adult or unsafe content
  10. Multiple regional Biogen domains linked, indicating global presence
Technical notes

Notes

The website is built on Adobe Experience Manager CMS, a robust enterprise platform suitable for complex content management needs. It uses jQuery 3.6.4 and Adobe Helix RUM for frontend interactivity and performance monitoring. Cookiebot manages cookie consent, ensuring GDPR compliance. Google Tag Manager and Google Analytics are integrated for marketing and analytics purposes. Hosting is on AWS infrastructure, indicated by AWS load balancer cookies. The site is mobile optimized with responsive design and uses modern meta tags for SEO. Performance is moderate, with potential improvements in loading speed and accessibility. The technical stack is modern and enterprise-grade, supporting scalability and security, though some security headers are missing.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with biogen.uy. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review biogen.uy.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.